Mayan Gilboa1,2, Michal Mandelboim2,3, Victoria Indenbaum3, Yaniv Lustig2,3, Carmit Cohen4, Galia Rahav1,2, Keren Asraf5, Sharon Amit6, Hanaa Jaber4, Ital Nemet3, Limor Kliker3, Erez Bar-Haim7, Ella Mendelson2,3, Ram Doolman5, Carmit Rubin4, Gili Regev-Yochay2,4, Yitshak Kreiss2,8. 1. Infectious Disease Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Central Virology Laboratory, Public Health Services, Ministry of Health, Tel Hashomer, Ramat Gan, Israel. 4. Infection Prevention and Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 5. Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 6. Clinical Microbiology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 7. Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Nes Ziona, Israel. 8. General Management, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Abstract
BACKGROUND: Despite high vaccine coverage, an increase in breakthrough coronavirus disease 2019 (COVID-19) infections, prompted administration of a third BNT162b2 dose to people aged >60 years in Israel since July 2021. Here, we report real-world immunogenicity following third dose. METHODS: Overall, 208 healthcare workers aged >60 years were included. Paired pre- and post-second and/or third dose immunoglobulin G (IgG) and neutralizing antibody titers were compared. A subpopulation of low responders to the second dose was also tested for T-cell activation. For 25 paired serum samples, we tested neutralization of wild-type vs neutralization of Delta and Lambda variants, pre- and post-third dose. Active surveillance of vaccine adverse events was conducted through surveys. RESULTS: A pronounced immune response was observed following the third dose, including a 33-fold and 51-fold increase in IgG and neutralizing antibody, respectively. The neutralizing antibody levels post-third dose were 9.34 times higher than post-second dose (geometric mean titer, 2598 [95% confidence interval {CI}, 2085-3237] vs 207 [95% CI, 126-339]). Nine previously low responders had a significant antibody increase post-third dose, and 7 of 9 showed increase in T-cell activation. Additionally, sera obtained post-third dose highly and comparably neutralized the wild-type and Delta and Lambda variants. Of 1056 responders to the adverse-event survey, none had serious events. CONCLUSIONS: We demonstrate a rapid and broad immune response to the third BNT162b2 dose in individuals >60 years of age.
BACKGROUND: Despite high vaccine coverage, an increase in breakthrough coronavirus disease 2019 (COVID-19) infections, prompted administration of a third BNT162b2 dose to people aged >60 years in Israel since July 2021. Here, we report real-world immunogenicity following third dose. METHODS: Overall, 208 healthcare workers aged >60 years were included. Paired pre- and post-second and/or third dose immunoglobulin G (IgG) and neutralizing antibody titers were compared. A subpopulation of low responders to the second dose was also tested for T-cell activation. For 25 paired serum samples, we tested neutralization of wild-type vs neutralization of Delta and Lambda variants, pre- and post-third dose. Active surveillance of vaccine adverse events was conducted through surveys. RESULTS: A pronounced immune response was observed following the third dose, including a 33-fold and 51-fold increase in IgG and neutralizing antibody, respectively. The neutralizing antibody levels post-third dose were 9.34 times higher than post-second dose (geometric mean titer, 2598 [95% confidence interval {CI}, 2085-3237] vs 207 [95% CI, 126-339]). Nine previously low responders had a significant antibody increase post-third dose, and 7 of 9 showed increase in T-cell activation. Additionally, sera obtained post-third dose highly and comparably neutralized the wild-type and Delta and Lambda variants. Of 1056 responders to the adverse-event survey, none had serious events. CONCLUSIONS: We demonstrate a rapid and broad immune response to the third BNT162b2 dose in individuals >60 years of age.
Authors: Manuela Tamburro; Giancarlo Ripabelli; Antonio D'Amico; Roberta De Dona; Mariagrazia Iafigliola; Albino Parente; Nicandro Samprati; Arturo Santagata; Carmen Adesso; Anna Natale; Michela Anna Di Palma; Fabio Cannizzaro; Michela Lucia Sammarco Journal: J Community Health Date: 2022-06-25
Authors: Francis Mwimanzi; Hope R Lapointe; Peter K Cheung; Yurou Sang; Fatima Yaseen; Gisele Umviligihozo; Rebecca Kalikawe; Sneha Datwani; F Harrison Omondi; Laura Burns; Landon Young; Victor Leung; Olga Agafitei; Siobhan Ennis; Winnie Dong; Simran Basra; Li Yi Lim; Kurtis Ng; Ralph Pantophlet; Chanson J Brumme; Julio S G Montaner; Natalie Prystajecky; Christopher F Lowe; Mari L DeMarco; Daniel T Holmes; Janet Simons; Masahiro Niikura; Marc G Romney; Zabrina L Brumme; Mark A Brockman Journal: J Infect Dis Date: 2022-09-21 Impact factor: 7.759
Authors: Francis Mwimanzi; Hope R Lapointe; Peter K Cheung; Yurou Sang; Fatima Yaseen; Gisele Umviligihozo; Rebecca Kalikawe; Sneha Datwani; F Harrison Omondi; Laura Burns; Landon Young; Victor Leung; Olga Agafitei; Siobhan Ennis; Winnie Dong; Simran Basra; Li Yi Lim; Kurtis Ng; Ralph Pantophlet; Chanson J Brumme; Julio S G Montaner; Natalie Prystajecky; Christopher F Lowe; Mari L DeMarco; Daniel T Holmes; Janet Simons; Masahiro Niikura; Marc G Romney; Zabrina L Brumme; Mark A Brockman Journal: medRxiv Date: 2022-02-21
Authors: Sara Y Tartof; Jeff M Slezak; Laura Puzniak; Vennis Hong; Timothy B Frankland; Bradley K Ackerson; Harpreet S Takhar; Oluwaseye A Ogun; Sarah R Simmons; Joann M Zamparo; Sharon Gray; Srinivas R Valluri; Kaije Pan; Luis Jodar; John M McLaughlin Journal: Lancet Reg Health Am Date: 2022-02-14
Authors: Giancarlo Ripabelli; Michela Lucia Sammarco; Giovanni Rezza; Antonio D'Amico; Roberta De Dona; Mariagrazia Iafigliola; Albino Parente; Nicandro Samprati; Arturo Santagata; Carmen Adesso; Anna Natale; Michela Anna Di Palma; Fabio Cannizzaro; Cosimo Dentizzi; Paola Stefanelli; Manuela Tamburro Journal: J Community Health Date: 2022-03-25